Healthcare Unfiltered

Latest Episodes:

Episode 48: Mid-Career Academic Transitions with Mikkael Sekeres and David Steensma Sep 14, 2021

Show notes

Mikkael Sekeres (@MikkaelSekeres), MD, chief of the division of hematology at the University of Miami Sylvester Comprehensive Cancer Center, and David Steensma (@DavidSteensma), MD, global hematology head at Novartis, share their recent experiences undergoing career transitions. The physicians dive into a discussion on how often fellowships are given to candidates who are pursuing academic careers, how and why the decisions were made to leave one institution for another (or an institution for industry), whether or not to interview for new positions discreetly, how to approach negotiating aspects of a new employment contract, and so much more.Read Dr. Sekeres' narrative about his move to Miami. https://ascopubs.org/doi/full/10.1200/JCO.21.01070Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. https://chadinabhan.com/Watch all Healthcare Unfiltered episodes on Youtube. https://www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Episode 47: Challenges for Young Academicians and Trainees With Sonikpreet Aulakh Sep 07, 2021

Show notes

Sonikpreet Aulakh (@SonikpreetA), MD, assistant professor of medicine at West Virginia University, provides valuable perspective on the transition into the academic world just two years after her fellowship. Dr. Aulakh sheds light on the experience and details of applying for jobs post-fellowship, what types of challenges she may face as a new faculty member, struggles she may encounter as an immigrant and a woman in applying for residency and faculty positions, and plenty more.

Episode 46: The FDA: The Gift that Keeps on Giving Aug 31, 2021

Show notes

Aaron Mitchell (@TheWonkologist), MD, MPH, medical oncologist and health outcomes researcher at Memorial Sloan Kettering Cancer Center, comes on to discuss the shortcomings and pitfalls of the regulatory processes at the FDA, optimal trial endpoints that provide the strongest evidence for approval, whether the accelerated approval process is enforced as it is written, what power any advisory panel really has when it comes to FDA approvals, and so many more pain points today.

Episode 45: Revisiting COVID-19: Variants and Vaccines Aug 24, 2021

Show notes

Chadi is rejoined by Priya Sampathkumar (@PSampathkumarMD), MD, infectious disease specialist and hospital epidemiologist, Mayo Clinic, to provide a state of affairs for the current COVID-19 situation in America, including why the country has failed to get more of its people vaccinated, why myocarditis has been a frequent side effects in some people, why the delta variant and other future variants come about, whether booster shots should be administered to healthy individuals and those who have had COVID-19 in the past, how safe it is for kids to return to in-person school, and more of the important talking points surrounding the virus at this time.

Episode 44: A Precise Depiction of Precision Medicine Aug 17, 2021

Show notes

Vivek Subbiah, MD, associate professor in the department of investigational cancer therapeutics, MD Anderson, is the world-renowned guest on the show this week to tackle the world of precision medicine in cancer. He begins by explaining how precision medicine is more than simply a “fancier” mechanism of treatment than chemotherapy, why tumor sequencing is important even though there aren’t drugs available for every possible mutation, how much the field has advanced even in the past 10 years, the intricacies of designing clinical trials, and lots more.

Episode 43: Peripheral T-Cell Lymphoma: Monitor or Transplantation? Aug 10, 2021

Show notes

For another lively debate, Chadi brings on two lymphoma experts to talk about what to do with peripheral T-cell lymphoma (PTCL) patients after an achieved remission: Barbara Pro (@bpromd), MD, Northwestern University, and Mehdi Hamadani (@MediHumdani), MD, Medical College of Wisconsin. The two doctors share how they counsel and treat patients in uncertain situations, including the “right” circumstances to watch-and-wait, autologous transplant, allogeneic transplant, or maintenance chemotherapy.

Episode 42: Smoldering Multiple Myeloma: To Treat or Not to Treat? Aug 03, 2021

Show notes

Chadi welcomes back Rafael Fonseca, (@Rfonsi1), MD, interim director of Mayo Clinic Cancer Center, and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, to debate whether smoldering multiple myeloma should be treated. They begin by agreeing on a definition of the disease, listing patient characteristics that may warrant consideration for early intervention, and stating the importance of improving the ability to predict progressing disease. The trio then debate treatment in specific example circumstances and the overall consensus within the myeloma world, the practicality of clinical trials for smoldering disease, and so much more in this testy and thought-provoking dialogue.

Episode 41: Docs Who Rock Jul 27, 2021

Show notes

Is it a coincidence that many clinicians are talented musicians? These doctors don’t believe so! In this exclusive roundtable pow-wow, Chadi hosts a range of crafty and passionate oncologists that share a similar dedication to music. Conversations on musical inspirations and favorite artists are interwoven with music samples and personal anecdotes in this truly lighthearted, uninhibited jam session like you’ve never heard.

Episode 40: The Whistleblower Who Changed Everything: Nancy Olivieri’s Story Jul 20, 2021

Show notes

In this captivating episode, Chadi shares the microphone with Nancy Olivieri (@DrNancyOlivieri), MD, professor of medicine, pediatrics, and public health science at the University of Toronto, to recount her famous clash with a pharmaceutical company (among other entities) that tried to silence her for reporting on adverse effects related to an experimental drug. Dr. Olivieri became famous for raising doubts about a drug that was being studied to treat patients with thalassemia. In great and juicy detail, Dr. Olivieri provides the timeline of events, including bouts with the company’s CEO as well as her own academic institution, and the legal battles that ensued.

Episode 39: R-CHOP versus DA-EPOCH-R for Double-Hit Lymphoma Jul 13, 2021

Show notes

Alan Skarbnik (@ASkarbnik), MD, director of the lymphoma and CLL program, Novant Health (Charlotte, NC), and Aaron Goodman (@AaronGoodman33), MD, hematologist, University of California San Diego, join the show for a long-awaited debate: treating double-hit lymphoma with R-CHOP vs dose-adjusted (DA)-EPOCH-R. The conversation gets testy when the trio describe double-hit lymphoma in terms of histology and phenotype, the limitations of retrospective analyses when it comes to establishing a standard of care for this type of lymphoma, an intense breakdown of the CALGB 50303 study as it relates to the treatment argument and toxicity profiles, and so much more.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected